Table 8. Open in new tab MIC and...

						Susceptibility
India
AMC^b	61	0.25	2	0.03	16	98.4	0.0	1.6	93.4 (98.4)	80.3	0.0	19.7
azithromycin	61	0.5	8	≤0.015	>256	NA	NA	NA	NA	NA	NA	NA
cefixime	37	0.5	0.5	0.06	1	NA	NA	NA	100	97.3	2.7	0.0
cefpodoxime	61	1	2	0.12	8	NA	NA	NA	45.9	NA	NA	NA
cefuroxime^c	59	2	16	0.25	64	81.4	6.8	11.9	23.7	0.0	81.4	18.6
ciprofloxacin	61	1	8	≤0.015	>32	67.2	0.0	32.8	67.2	34.4	0.0	65.6
clarithromycin	49	0.5	8	≤0.015	64	NA	NA	NA	NA	NA	NA	NA
levofloxacin	61	1	8	0.03	>32	80.3	0.0	19.7	80.3	57.4	0.0	42.6
South Korea
AMC^b	18	0.12	0.25	≤0.015	0.25	100	0.0	0.0	100 (100)	100	0.0	0.0
azithromycin	4	0.12	>256	0.06	>256	NA	NA	NA	NA	NA	NA	NA
cefaclor	18	0.5	1	≤0.015	1	100	0.0	0.0	50.0	NA	NA	NA
cefuroxime^c	18	1	2	0.03	2	100	0.0	0.0	50.0	5.6	94.4	0.0
ciprofloxacin	18	0.06	0.12	0.03	0.12	100	0.0	0.0	100	100	0.0	0.0
clarithromycin	18	0.5	2	0.12	>256	NA	NA	NA	NA	NA	NA	NA
levofloxacin	18	0.03	0.06	0.03	0.06	100	0.0	0.0	100	100	0.0	0.0
Singapore
AMC^b	15	0.06	0.25	≤0.015	0.5	100	0.0	0.0	100 (100)	100	0.0	0.0
azithromycin	20	0.12	0.25	0.12	0.5	NA	NA	NA	NA	NA	NA	NA
cefaclor	20	2	4	1	4	100	0.0	0.0	0.0	NA	NA	NA
cefuroxime^c	14	1	2	0.12	4	100	0.0	0.0	57.1	7.1	92.9	0
ciprofloxacin	20	0.06	0.06	0.03	0.5	100	0.0	0.0	100	100	0.0	0.0
clarithromycin	20	0.25	0.25	0.03	0.5	NA	NA	NA	NA	NA	NA	NA
levofloxacin	20	0.06	0.06	0.03	0.06	100	0.0	0.0	100	100	0.0	0.0
moxifloxacin	20	0.06	0.06	0.06	0.06	NA	NA	NA	100	100	0.0	0.0
Thailand
AMC^b	49	0.25	0.5	0.03	0.5	100	0.0	0.0	100 (100)	100	0.0	0.0
azithromycin	49	0.25	1	≤0.015	>256	NA	NA	NA	NA	NA	NA	NA
cefuroxime^c	49	1	2	0.06	4	100	0.0	0.0	63.3	2.0	98.0	0.0
clarithromycin	49	0.25	1	0.03	>256	NA	NA	NA	NA	NA	NA	NA
levofloxacin	49	0.06	0.12	0.03	>32	98.0	0.0	2.0	98.0	98.0	0.0	2.0

Susceptibility

MIC (mg/L)

CLSI

PK/PD

EUCAST

Antimicrobial

n^a

50%

90%

min

max

India

AMC^b

0.25

0.03

98.4

0.0

1.6

93.4 (98.4)

80.3

0.0

19.7

azithromycin

0.5

≤0.015

>256

cefixime

0.5

0.06

100

97.3

2.7

0.0

cefpodoxime

0.12

45.9

cefuroxime^c

0.25

81.4

6.8

11.9

23.7

0.0

81.4

18.6

ciprofloxacin

≤0.015

>32

67.2

0.0

32.8

67.2

34.4

0.0

65.6

clarithromycin

0.5

≤0.015

levofloxacin

0.03

>32

80.3

0.0

19.7

80.3

57.4

0.0

42.6

South Korea

AMC^b

0.12

0.25

≤0.015

0.25

100

0.0

100 (100)

100

0.0

azithromycin

0.12

>256

0.06

>256

cefaclor

0.5

≤0.015

100

0.0

50.0

cefuroxime^c

0.03

100

0.0

50.0

5.6

94.4

0.0

ciprofloxacin

0.06

0.12

0.03

0.12

100

0.0

100

0.0

clarithromycin

0.5

0.12

>256

levofloxacin

0.03

0.06

0.03

0.06

100

0.0

100

0.0

Singapore

AMC^b

0.06

0.25

≤0.015

0.5

100

0.0

100 (100)

100

0.0

azithromycin

0.12

0.25

0.12

0.5

cefaclor

100

0.0

cefuroxime^c

0.12

100

0.0

57.1

7.1

92.9

ciprofloxacin

0.06

0.03

0.5

100

0.0

100

0.0

clarithromycin

0.25

0.03

0.5

levofloxacin

0.06

0.03

0.06

100

0.0

100

0.0

moxifloxacin

0.06

100

0.0

Thailand

AMC^b

0.25

0.5

0.03

0.5

100

0.0

100 (100)

100

0.0

azithromycin

0.25

≤0.015

>256

cefuroxime^c

0.06

100

0.0

63.3

2.0

98.0

0.0

clarithromycin

0.25

0.03

>256

levofloxacin

0.06

0.12

0.03

>32

98.0

0.0

2.0

98.0

0.0

2.0

						Susceptibility
India
AMC^b	61	0.25	2	0.03	16	98.4	0.0	1.6	93.4 (98.4)	80.3	0.0	19.7
azithromycin	61	0.5	8	≤0.015	>256	NA	NA	NA	NA	NA	NA	NA
cefixime	37	0.5	0.5	0.06	1	NA	NA	NA	100	97.3	2.7	0.0
cefpodoxime	61	1	2	0.12	8	NA	NA	NA	45.9	NA	NA	NA
cefuroxime^c	59	2	16	0.25	64	81.4	6.8	11.9	23.7	0.0	81.4	18.6
ciprofloxacin	61	1	8	≤0.015	>32	67.2	0.0	32.8	67.2	34.4	0.0	65.6
clarithromycin	49	0.5	8	≤0.015	64	NA	NA	NA	NA	NA	NA	NA
levofloxacin	61	1	8	0.03	>32	80.3	0.0	19.7	80.3	57.4	0.0	42.6
South Korea
AMC^b	18	0.12	0.25	≤0.015	0.25	100	0.0	0.0	100 (100)	100	0.0	0.0
azithromycin	4	0.12	>256	0.06	>256	NA	NA	NA	NA	NA	NA	NA
cefaclor	18	0.5	1	≤0.015	1	100	0.0	0.0	50.0	NA	NA	NA
cefuroxime^c	18	1	2	0.03	2	100	0.0	0.0	50.0	5.6	94.4	0.0
ciprofloxacin	18	0.06	0.12	0.03	0.12	100	0.0	0.0	100	100	0.0	0.0
clarithromycin	18	0.5	2	0.12	>256	NA	NA	NA	NA	NA	NA	NA
levofloxacin	18	0.03	0.06	0.03	0.06	100	0.0	0.0	100	100	0.0	0.0
Singapore
AMC^b	15	0.06	0.25	≤0.015	0.5	100	0.0	0.0	100 (100)	100	0.0	0.0
azithromycin	20	0.12	0.25	0.12	0.5	NA	NA	NA	NA	NA	NA	NA
cefaclor	20	2	4	1	4	100	0.0	0.0	0.0	NA	NA	NA
cefuroxime^c	14	1	2	0.12	4	100	0.0	0.0	57.1	7.1	92.9	0
ciprofloxacin	20	0.06	0.06	0.03	0.5	100	0.0	0.0	100	100	0.0	0.0
clarithromycin	20	0.25	0.25	0.03	0.5	NA	NA	NA	NA	NA	NA	NA
levofloxacin	20	0.06	0.06	0.03	0.06	100	0.0	0.0	100	100	0.0	0.0
moxifloxacin	20	0.06	0.06	0.06	0.06	NA	NA	NA	100	100	0.0	0.0
Thailand
AMC^b	49	0.25	0.5	0.03	0.5	100	0.0	0.0	100 (100)	100	0.0	0.0
azithromycin	49	0.25	1	≤0.015	>256	NA	NA	NA	NA	NA	NA	NA
cefuroxime^c	49	1	2	0.06	4	100	0.0	0.0	63.3	2.0	98.0	0.0
clarithromycin	49	0.25	1	0.03	>256	NA	NA	NA	NA	NA	NA	NA
levofloxacin	49	0.06	0.12	0.03	>32	98.0	0.0	2.0	98.0	98.0	0.0	2.0

Table 8.

Open in new tab

MIC and susceptibility results for M. catarrhalis isolates by country

						Susceptibility
		MIC (mg/L)				CLSI			PK/PD	EUCAST
Antimicrobial	n^a	50%	90%	min	max	%S	%I	%R	%S	%S	%I	%R
India
AMC^b	61	0.25	2	0.03	16	98.4	0.0	1.6	93.4 (98.4)	80.3	0.0	19.7
azithromycin	61	0.5	8	≤0.015	>256	NA	NA	NA	NA	NA	NA	NA
cefixime	37	0.5	0.5	0.06	1	NA	NA	NA	100	97.3	2.7	0.0
cefpodoxime	61	1	2	0.12	8	NA	NA	NA	45.9	NA	NA	NA
cefuroxime^c	59	2	16	0.25	64	81.4	6.8	11.9	23.7	0.0	81.4	18.6
ciprofloxacin	61	1	8	≤0.015	>32	67.2	0.0	32.8	67.2	34.4	0.0	65.6
clarithromycin	49	0.5	8	≤0.015	64	NA	NA	NA	NA	NA	NA	NA
levofloxacin	61	1	8	0.03	>32	80.3	0.0	19.7	80.3	57.4	0.0	42.6
South Korea
AMC^b	18	0.12	0.25	≤0.015	0.25	100	0.0	0.0	100 (100)	100	0.0	0.0
azithromycin	4	0.12	>256	0.06	>256	NA	NA	NA	NA	NA	NA	NA
cefaclor	18	0.5	1	≤0.015	1	100	0.0	0.0	50.0	NA	NA	NA
cefuroxime^c	18	1	2	0.03	2	100	0.0	0.0	50.0	5.6	94.4	0.0
ciprofloxacin	18	0.06	0.12	0.03	0.12	100	0.0	0.0	100	100	0.0	0.0
clarithromycin	18	0.5	2	0.12	>256	NA	NA	NA	NA	NA	NA	NA
levofloxacin	18	0.03	0.06	0.03	0.06	100	0.0	0.0	100	100	0.0	0.0
Singapore
AMC^b	15	0.06	0.25	≤0.015	0.5	100	0.0	0.0	100 (100)	100	0.0	0.0
azithromycin	20	0.12	0.25	0.12	0.5	NA	NA	NA	NA	NA	NA	NA
cefaclor	20	2	4	1	4	100	0.0	0.0	0.0	NA	NA	NA
cefuroxime^c	14	1	2	0.12	4	100	0.0	0.0	57.1	7.1	92.9	0
ciprofloxacin	20	0.06	0.06	0.03	0.5	100	0.0	0.0	100	100	0.0	0.0
clarithromycin	20	0.25	0.25	0.03	0.5	NA	NA	NA	NA	NA	NA	NA
levofloxacin	20	0.06	0.06	0.03	0.06	100	0.0	0.0	100	100	0.0	0.0
moxifloxacin	20	0.06	0.06	0.06	0.06	NA	NA	NA	100	100	0.0	0.0
Thailand
AMC^b	49	0.25	0.5	0.03	0.5	100	0.0	0.0	100 (100)	100	0.0	0.0
azithromycin	49	0.25	1	≤0.015	>256	NA	NA	NA	NA	NA	NA	NA
cefuroxime^c	49	1	2	0.06	4	100	0.0	0.0	63.3	2.0	98.0	0.0
clarithromycin	49	0.25	1	0.03	>256	NA	NA	NA	NA	NA	NA	NA
levofloxacin	49	0.06	0.12	0.03	>32	98.0	0.0	2.0	98.0	98.0	0.0	2.0

						Susceptibility
		MIC (mg/L)				CLSI			PK/PD	EUCAST
Antimicrobial	n^a	50%	90%	min	max	%S	%I	%R	%S	%S	%I	%R
India
AMC^b	61	0.25	2	0.03	16	98.4	0.0	1.6	93.4 (98.4)	80.3	0.0	19.7
azithromycin	61	0.5	8	≤0.015	>256	NA	NA	NA	NA	NA	NA	NA
cefixime	37	0.5	0.5	0.06	1	NA	NA	NA	100	97.3	2.7	0.0
cefpodoxime	61	1	2	0.12	8	NA	NA	NA	45.9	NA	NA	NA
cefuroxime^c	59	2	16	0.25	64	81.4	6.8	11.9	23.7	0.0	81.4	18.6
ciprofloxacin	61	1	8	≤0.015	>32	67.2	0.0	32.8	67.2	34.4	0.0	65.6
clarithromycin	49	0.5	8	≤0.015	64	NA	NA	NA	NA	NA	NA	NA
levofloxacin	61	1	8	0.03	>32	80.3	0.0	19.7	80.3	57.4	0.0	42.6
South Korea
AMC^b	18	0.12	0.25	≤0.015	0.25	100	0.0	0.0	100 (100)	100	0.0	0.0
azithromycin	4	0.12	>256	0.06	>256	NA	NA	NA	NA	NA	NA	NA
cefaclor	18	0.5	1	≤0.015	1	100	0.0	0.0	50.0	NA	NA	NA
cefuroxime^c	18	1	2	0.03	2	100	0.0	0.0	50.0	5.6	94.4	0.0
ciprofloxacin	18	0.06	0.12	0.03	0.12	100	0.0	0.0	100	100	0.0	0.0
clarithromycin	18	0.5	2	0.12	>256	NA	NA	NA	NA	NA	NA	NA
levofloxacin	18	0.03	0.06	0.03	0.06	100	0.0	0.0	100	100	0.0	0.0
Singapore
AMC^b	15	0.06	0.25	≤0.015	0.5	100	0.0	0.0	100 (100)	100	0.0	0.0
azithromycin	20	0.12	0.25	0.12	0.5	NA	NA	NA	NA	NA	NA	NA
cefaclor	20	2	4	1	4	100	0.0	0.0	0.0	NA	NA	NA
cefuroxime^c	14	1	2	0.12	4	100	0.0	0.0	57.1	7.1	92.9	0
ciprofloxacin	20	0.06	0.06	0.03	0.5	100	0.0	0.0	100	100	0.0	0.0
clarithromycin	20	0.25	0.25	0.03	0.5	NA	NA	NA	NA	NA	NA	NA
levofloxacin	20	0.06	0.06	0.03	0.06	100	0.0	0.0	100	100	0.0	0.0
moxifloxacin	20	0.06	0.06	0.06	0.06	NA	NA	NA	100	100	0.0	0.0
Thailand
AMC^b	49	0.25	0.5	0.03	0.5	100	0.0	0.0	100 (100)	100	0.0	0.0
azithromycin	49	0.25	1	≤0.015	>256	NA	NA	NA	NA	NA	NA	NA
cefuroxime^c	49	1	2	0.06	4	100	0.0	0.0	63.3	2.0	98.0	0.0
clarithromycin	49	0.25	1	0.03	>256	NA	NA	NA	NA	NA	NA	NA
levofloxacin	49	0.06	0.12	0.03	>32	98.0	0.0	2.0	98.0	98.0	0.0	2.0

min, minimum; max, maximum; S, susceptible; I, intermediate; AMC, amoxicillin/clavulanic acid; NA, no breakpoint data available (NA for azithromycin and clarithromycin by CLSI, PK/PD or EUCAST because Etest^® breakpoints in CO₂ not available).

^aNot all isolates were tested.

^bPK/PD susceptibility at high dose is shown in parentheses.

^cBreakpoints used are for cefuroxime axetil.

This Feature Is Available To Subscribers Only